Spectacular advances creating a revolution in the diagnosis and treatment of male infertility

May 29, 2024 02:42 PM AEST | By Cision
 Spectacular advances creating a revolution in the diagnosis and treatment of male infertility
Image source: Kalkine Media

MANILA, Philippines, May 29, 2024 /PRNewswire/ -- Spectacular advances in the diagnosis and treatment of male infertility are offering new hope to the one in six couples globally who seek assisted reproduction to achieve their dreams of parenthood.

A major conference on human reproduction in the Philippines this week addressed emerging frontiers of understanding about male infertility and sexual dysfunction that is responsible for about half of all causes of couples failing to conceive.

Eminent Indian andrologist and microsurgeon, Dr Rupin Shah, a keynote speaker at the 2024 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE), said the treatment of male infertility was on the cusp of a scientific and medical revolution.

"In the past, semen analysis was the main test to label a man infertile," he explained. "However, we now recognise that measurement of sperm count and motility tells only part of the story.

"The World Health Organisation has taken the bold step of declaring that there is no definite reference value that can label one man infertile and another fertile.

"Therefore, future research is expected to quantify semen parameters on a continuum that gives the probability of fertility rather than a definite label of fertile or infertile."

Dr Shah said the future of male infertility treatment would be driven by automatic semen analysis powered by artificial intelligence along with compact computing power allowing home semen testing that will be convenient and private resulting in earlier detection and corrective procedures.

He said there would be a dynamic new focus on sperm DNA integrity and testing of genetic variants and defects analysed by AI programs that will lead to more personalised medicine and treatments tailored to specific individual profiles.

There will also be a growing need to address spermatotoxic agents impacting on male infertility.

"The radio waves that bombard us, the chemicals we inhale, the endocrine disruptors that permeate our food cycle, and the microplastics that we have unleashed into the environment all play havoc with our fertility, and it is no surprise that sperm counts have been plummeting globally," Dr Shah added.

"To safeguard our species, future tests of an infertile male will have to include an assessment of accumulated toxic products with subsequent treatments to neutralise these impacts.

"Fascinating evidence is also emerging that the paternal influence on the offspring is much more pervasive, and the father's health at the time of conception can impact the future health of the offspring through epigenetic modifications that alter the expression of the genes.

"In future, we can expect that male evaluation will include profiling of various mRNA markers in the semen to better understand the testicular function and sperm quality."

Dr Shah said the development of artificial sperm would represent a "final frontier" in the treatment of male infertility.

"In the body, can we introduce stem cells into a non-functioning testis and induce it to start making sperm?

"In the laboratory, can we take immature cells from which sperm develop and mature them into viable sperm, or can we take an early development stem cell (pluripotent) and coax it into growing and transforming into a sperm cell?

"Can we take a genetically defective cell, repair the genetic defect and then replace it in the testis where it will produce normal sperm?

"This all sounds far-fetched, but these things have already been achieved in animal studies. Only the final frontier remains – human application.

"Of course, there are many barriers to overcome. For example, how do we make the process efficient enough for routine use? Is it safe for the offspring? And what are the tricky ethical consequences of such treatments?

"However, the development of these revolutionary treatments in the future is very much a possibility."

For further information, go to the ASPIRE Congress website www.aspire2024.com  


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.